MS Patients Might Benefit From New Oral Drug


Still, more research might be needed before BG-12 becomes more widely available, even after this two-year study.

"[Two years] is the standard these days, but the question is: is it adequate?" said Dr. John Corboy, professor and director of the department of neurology at the University of Colorado. "[It] is quite long in general, but very short when you consider the typical duration someone has MS."

Dr. Timothy Coetzee, chief research officer of the National MS Society, agreed. "As with any new therapy, it's important to do follow-up studies to understand the impact of the treatment over the long term," he said. "This will help us gain more specific knowledge of the long-term impact of this treatment on the immune system as well as the nervous system."

Today, Yoho's past participation allows him to continue taking the drug, and he said he hopes that his participation in the research will one day help others to benefit from the research.

"The coolest part about the study, I get to help finding a medication that really helps," Yoho said. "That's really cool."

  • 1
  • |
  • 2
Join the Discussion
blog comments powered by Disqus
You Might Also Like...